David A. Siegel Alx Oncology Holdings Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 500,500 shares of ALXO stock, worth $610,610. This represents 0.0% of its overall portfolio holdings.

Number of Shares

500,500

Previous 67,600 640.38%

Holding current value

$610,610

Previous $407,000 123.59%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.81 - $8.13 $783,549 - $3.52 Million	432,900 Added 640.38%	500,500 $910,000
Q2 2024 Aug 14, 2024	BUY	$5.84 - $17.56 $336,384 - $1.01 Million	57,600 Added 576.0%	67,600 $407,000
Q1 2024 May 15, 2024	BUY	$10.95 - $16.79 $109,500 - $167,900	10,000 New	10,000 $111,000
Q3 2023 Nov 14, 2023	SELL	$4.19 - $7.35 $144,974 - $254,310	-34,600 Reduced 74.89%	11,600 $55,000
Q2 2023 Aug 14, 2023	SELL	$4.37 - $9.56 $322,506 - $705,528	-73,800 Reduced 61.5%	46,200 $346,000
Q1 2023 May 15, 2023	BUY	$4.52 - $11.71 $154,583 - $400,482	34,200 Added 39.86%	120,000 $542,000
Q4 2022 Feb 14, 2023	SELL	$9.51 - $12.95 $228,240 - $310,800	-24,000 Reduced 21.86%	85,800 $966,000
Q3 2022 Nov 14, 2022	SELL	$8.23 - $15.14 $418,907 - $770,626	-50,900 Reduced 31.67%	109,800 $1.05 Million
Q2 2022 Aug 15, 2022	BUY	$5.89 - $19.46 $282,131 - $932,134	47,900 Added 42.46%	160,700 $1.3 Million
Q1 2022 May 16, 2022	SELL	$13.65 - $22.06 $604,695 - $977,258	-44,300 Reduced 28.2%	112,800 $1.91 Million
Q4 2021 Feb 14, 2022	BUY	$21.49 - $74.4 $3.38 Million - $11.7 Million	157,100 New	157,100 $3.38 Million

Others Institutions Holding ALXO

# of Institutions

101

Shares Held

39.7M

Call Options Held

134K

Put Options Held

17.4K

View Full List

About ALX ONCOLOGY HOLDINGS INC

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $49.7M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

More about ALXO

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account